Granules India Ltd
Granules India Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Granules India anticipates meaningful revenue growth driven by launches of 3-4 complex generic products, including CNS, ADHD, and controlled substances, within the next 1 to 1.5 years. - Launch of 1-2 existing products from the Genome Valley facility over the next 1-2 quarters to cater to additional demand, with incremental revenue expected. - Continued focus on complex generics such as oncology, CNS, and controlled substances, contributing to a larger share of filings and revenues. - Growth in the U.S. Granules India expects meaningful growth from 3-4 product launches within the next 1 to 1.5 years, particularly in complex generics like CNS, ADHD, and controlled substances.
From Granules India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Granules India anticipates meaningful revenue growth driven by launches of 3-4 complex generic products, including CNS, ADHD, and controlled substances, within the next 1 to 1.5 years.
- Launch of 1-2 existing products from the Genome Valley facility over the next 1-2 quarters to cater to additional demand, with incremental revenue expected.
- Continued focus on complex generics such as oncology, CNS, and controlled substances, contributing to a larger share of filings and revenues.
- Growth in the U.S. market via early generic launches for limited competition products like lisdexamfetamine and generic Adzenys with significant market share potential.
- Steady expansion supported by operational efficiencies and increased capacity utilization at Gagillapur and GLS sites.
2 more points from Granules India Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Granules India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Granules is investing in system enhancements involving capex and opex over upcoming quarters to strengthen operational reliability and resilience.
- Expansion plans include capacity expansion supported by proceeds from a recent preferential issue aimed at enhancing financial flexibility.
- New plants, including an API plant in Vizag with advanced automation (DCS-driven, paperless documentation), are under development.
- Continued focus on digitalization and automation, especially at Gagillapur (implementation expected by mid-calendar year), to improve quality and compliance.
- Investment will also support scaling operations at GLS facility as regulatory milestones are achieved.
2 more points from Granules India Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Granules India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Granules India Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Granules India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.5K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Granules India Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Wanbury Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Ind-Swift Laboratories Ltd (Q3 FY26)
Q2 FY26 Revenue: ₹152.64 Cr (Total Income: ₹170.50 Cr), with a year-on-year (Y-o-Y) increase of 1.91%. Key investor presentation takeaways from Ind-Swift Labora
- Caplin Point Laboratories Ltd (Q3 FY26)
Approximately INR 385 crores has already been spent; the remainder is planned over the next 12 to 18 months. Key concall takeaways from Caplin Point…
Arthneeti Pro · Annual
Granules India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Granules India Ltd Q3 FY26 results?
Granules India anticipates meaningful revenue growth driven by launches of 3-4 complex generic products, including CNS, ADHD, and controlled substances, within the next 1 to 1.5 years. - Launch of 1-2 existing products from the Genome Valley facility over the next 1-2 quarters to cater to additional demand, with incremental revenue expected. - Continued focus on complex generics such as oncology, CNS, and controlled substances, contributing to a larger share of filings and revenues. - Growth in the U.S. Granules India expects meaningful growth from 3-4 product launches within the next 1 to 1.5 years, particularly in complex generics like CNS, ADHD, and controlled substances.
What is Granules India Ltd share price analysis?
Granules India Ltd currently shows a neutral. The stock trades at a P/E of 32.2 with a market cap of ₹20,941 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India Ltd planning capital expenditure?
Granules is investing in system enhancements involving capex and opex over upcoming quarters to strengthen operational reliability and resilience.
Keep Granules India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.